Prognostic value and efficacy evaluation of novel drugs for cytogenetic aberrations in multiple myeloma: a meta-analysis.

Yu, Wenjun; Li, Jianyong; Chen, Lijuan

Yu, Wenjun; Li, Jianyong; Chen, Lijuan.

Afiliação

Yu W; Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital Nanjing, China.
Li J; Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital Nanjing, China.
Chen L; Department of Hematology, First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital Nanjing, China.

Int J Clin Exp Med ; 7(11): 4051-62, 2014.

Article em En | MEDLINE | ID: mdl-25550914

Palavras-chave

Cytogenetic aberrations; bortezomib; lenalidomide; meta-analysis; multiple myeloma; prognosis

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Systematic_reviews Idioma: En Revista: Int J Clin Exp Med Ano de publicação: 2014 Tipo de documento: Article País de afiliação: China

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google